Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:EOLS NASDAQ:RXRX NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$67.50+2.3%$59.09$11.40▼$72.36$1.92B0.72557,957 shs706,086 shsEOLSEvolus$6.94-2.7%$6.32$3.86▼$10.20$469.54M1.34751,001 shs596,307 shsRXRXRecursion Pharmaceuticals$3.67-0.5%$3.30$2.77▼$7.18$1.96B1.0419.94 million shs23.11 million shsTSHATaysha Gene Therapies$6.81+1.2%$6.13$2.25▼$7.30$1.93B1.193.60 million shs6.66 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+4.47%+9.97%+18.50%+18.95%+193.59%EOLSEvolus0.00%+8.19%+8.69%+73.48%-21.99%RXRXRecursion Pharmaceuticals+4.83%+16.04%+2.79%+20.39%-26.64%TSHATaysha Gene Therapies+6.15%+3.06%+14.65%+50.56%+182.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$67.50+2.3%$59.09$11.40▼$72.36$1.92B0.72557,957 shs706,086 shsEOLSEvolus$6.94-2.7%$6.32$3.86▼$10.20$469.54M1.34751,001 shs596,307 shsRXRXRecursion Pharmaceuticals$3.67-0.5%$3.30$2.77▼$7.18$1.96B1.0419.94 million shs23.11 million shsTSHATaysha Gene Therapies$6.81+1.2%$6.13$2.25▼$7.30$1.93B1.193.60 million shs6.66 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+4.47%+9.97%+18.50%+18.95%+193.59%EOLSEvolus0.00%+8.19%+8.69%+73.48%-21.99%RXRXRecursion Pharmaceuticals+4.83%+16.04%+2.79%+20.39%-26.64%TSHATaysha Gene Therapies+6.15%+3.06%+14.65%+50.56%+182.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.69Moderate Buy$81.8221.21% UpsideEOLSEvolus 2.50Moderate Buy$16.00130.55% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10120.71% UpsideTSHATaysha Gene Therapies 3.00Buy$12.6285.25% UpsideCurrent Analyst Ratings BreakdownLatest EOLS, RXRX, ANAB, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/30/2026TSHATaysha Gene Therapies Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.006/24/2026TSHATaysha Gene Therapies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026TSHATaysha Gene Therapies Pivotal ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.006/23/2026TSHATaysha Gene Therapies BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $14.006/23/2026TSHATaysha Gene Therapies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/23/2026TSHATaysha Gene Therapies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $11.006/22/2026TSHATaysha Gene Therapies Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.006/22/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/17/2026EOLSEvolus BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/15/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M8.37N/AN/A$1.34 per share50.37EOLSEvolus$297.18M1.54N/AN/A($0.36) per share-19.28RXRXRecursion Pharmaceuticals$65.74M29.58N/AN/A$2.14 per share1.71TSHATaysha Gene Therapies$9.77M200.30N/AN/A$0.90 per share7.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A20.77N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)EOLSEvolus-$51.64M-$0.67N/A115.67N/A-14.39%N/A-19.03%8/4/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest EOLS, RXRX, ANAB, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58EOLSEvolusN/A2.041.68RXRXRecursion Pharmaceuticals0.015.475.47TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AEOLSEvolus90.69%RXRXRecursion Pharmaceuticals89.06%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%EOLSEvolus5.00%RXRXRecursion Pharmaceuticals6.65%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableEOLSEvolus17065.86 million62.56 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableEOLS, RXRX, ANAB, and TSHA HeadlinesRecent News About These CompaniesTaysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label PotentialJune 30 at 10:04 AM | seekingalpha.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsJune 29 at 2:26 AM | americanbankingnews.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 25, 2026 | finanznachrichten.deTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical ...June 25, 2026 | enidnews.comETaysha Gene Therapies Announces Major Equity Financing DealJune 25, 2026 | tipranks.comTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingJune 25, 2026 | globenewswire.comTaysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200MJune 25, 2026 | msn.comTaysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | quiverquant.comQTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and AbbVie (ABBV)June 23, 2026 | theglobeandmail.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - SlideshowJune 23, 2026 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome TranscriptJune 22, 2026 | seekingalpha.comTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 ...June 22, 2026 | markets.businessinsider.comTaysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)June 22, 2026 | msn.comTaysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year RecoveryJune 13, 2026 | finance.yahoo.comIs Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comTaysha Gene Therapies Grants Restricted Stock Units and Stock Options to New EmployeesJune 5, 2026 | quiverquant.comQTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comTaysha Gene Therapies Shareholders Back Governance and LeadershipJune 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEOLS, RXRX, ANAB, and TSHA Company DescriptionsAnaptysBio NASDAQ:ANAB$67.50 +1.53 (+2.32%) Closing price 04:00 PM EasternExtended Trading$67.44 -0.06 (-0.08%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Evolus NASDAQ:EOLS$6.94 -0.19 (-2.66%) Closing price 04:00 PM EasternExtended Trading$6.94 -0.01 (-0.07%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Recursion Pharmaceuticals NASDAQ:RXRX$3.67 -0.02 (-0.54%) Closing price 04:00 PM EasternExtended Trading$3.67 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Taysha Gene Therapies NASDAQ:TSHA$6.81 +0.08 (+1.19%) Closing price 04:00 PM EasternExtended Trading$6.91 +0.10 (+1.47%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
